171 related articles for article (PubMed ID: 36615897)
1. Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study.
Sobolewska-Włodarczyk A; Walecka-Kapica E; Włodarczyk M; Gąsiorowska A
Nutrients; 2023 Jan; 15(1):. PubMed ID: 36615897
[No Abstract] [Full Text] [Related]
2. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
4. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
5. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
[TBL] [Abstract][Full Text] [Related]
7. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S
Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009
[TBL] [Abstract][Full Text] [Related]
8. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
Shapina MV; Nanaeva BA
Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
[TBL] [Abstract][Full Text] [Related]
9. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
[TBL] [Abstract][Full Text] [Related]
10. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
[TBL] [Abstract][Full Text] [Related]
11. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
[TBL] [Abstract][Full Text] [Related]
12. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
Narula N; Wong ECL; Marshall JK; Jairath V; Dulai PS; Reinisch W
Am J Gastroenterol; 2023 Jan; 118(1):121-128. PubMed ID: 36066459
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study.
Zagórowicz E; Cichoż-Lach H; Kopertowska-Majchrzak M; Eder P; Stawczyk-Eder K; Talar-Wojnarowska R; Zatorski H; Solarska-Półchłopek A; Filip R; Janiak M; Skrobot K; Kłopocka M; Liebert A; Kaczka A; Wojciechowski K; Drygała S; Michalak A
Adv Clin Exp Med; 2024 Jan; 33(1):69-77. PubMed ID: 37166016
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
[TBL] [Abstract][Full Text] [Related]
16. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
Quénéhervé L; Trang-Poisson C; Fantou A; Flamant M; Durand T; Bouguen G; Bregeon J; Oullier T; Amil M; Dewitte M; Bardot S; Blandin S; Braudeau C; Vibet MA; Josien R; Neunlist M; Bourreille A
PLoS One; 2024; 19(4):e0298313. PubMed ID: 38564601
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.
Bamias G; Kokkotis G; Gizis M; Kapizioni C; Karmiris K; Koureta E; Kyriakos N; Leonidakis G; Makris K; Markopoulos P; Michalopoulos G; Michopoulos S; Papaconstantinou I; Polymeros D; Siakavellas SI; Triantafyllou K; Tsironi E; Tsoukali E; Tzouvala M; Viazis N; Xourafas V; Zacharopoulou E; Zampeli E; Zografos K; Papatheodoridis G; Mantzaris G
Dig Dis Sci; 2022 Mar; 67(3):1007-1017. PubMed ID: 33751325
[TBL] [Abstract][Full Text] [Related]
18. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
[TBL] [Abstract][Full Text] [Related]
19. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
Waljee AK; Liu B; Sauder K; Zhu J; Govani SM; Stidham RW; Higgins PDR
Aliment Pharmacol Ther; 2018 Mar; 47(6):763-772. PubMed ID: 29359519
[TBL] [Abstract][Full Text] [Related]
20. Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
Loftus EV; Colombel JF; Feagan BG; Vermeire S; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):400-411. PubMed ID: 27683800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
